Skip to main content
Opthea Ltd logo

Opthea Ltd — Investor Relations & Filings

Ticker · OPT ISIN · US68386J2087 LEI · 549300Q5FMFDLP46SF83 ASX Manufacturing
Open in API
Filings indexed 1,390 across all filing types
Latest filing 2017-10-22 AGM Information
Country AU Australia
Listing ASX OPT

About Opthea Ltd

https://opthea.com/

Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for vision-threatening retinal diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company's lead product candidate, sozinibercept, is a first-in-class biologic 'trap' inhibitor targeting Vascular Endothelial Growth Factors C and D (VEGF-C and VEGF-D). Sozinibercept is being developed for administration in combination with standard-of-care anti-VEGF-A therapies. This dual-pathway inhibition aims to deliver superior visual outcomes by more comprehensively blocking the mechanisms that contribute to disease progression, addressing the limitations of current treatments that only target VEGF-A. The therapy is being evaluated in late-stage pivotal clinical trials for wet AMD.

Recent filings

Filing Released Lang Actions
Notice of Annual General Meeting and Proxy Form 19 pages 909.1KB
AGM Information Classification · 100% confidence The document is titled 'Notice of annual general meeting and explanatory notes' and includes details about the date, time, and location of the AGM. It contains the notice of meeting, explanatory notes about resolutions to be voted on, proxy voting instructions, and other procedural information related to the AGM. It references the financial statements, directors' report, and auditor's report to be received at the meeting but does not contain the reports themselves. The document also includes resolutions for re-election of a director, adoption of remuneration report, ratification of prior share issue, and approval of additional placement capacity, all typical contents of an AGM notice. The document is about the meeting and voting process, not the actual annual report or financial statements. Therefore, it fits the category of AGM Information (AGM-R).
2017-10-22 English
Opthea Granted Key United States Patent Covering OPT-302 3 pages 73.0KB
Capital/Financing Update Classification · 90% confidence The document is an ASX and media release dated 31 August 2017 announcing the grant of a key United States patent for the company's drug OPT-302. It discusses patent details, clinical trial plans, and background information about the drug and disease. There are no financial statements, earnings data, or regulatory filings such as certifications. The document is a corporate announcement about intellectual property and clinical development progress, not a financial report or regulatory filing. It does not fit categories like Annual Report, Earnings Release, or Regulatory Filings. It is a capital/financing update type of announcement related to intellectual property and future clinical trial plans, which aligns best with Capital/Financing Update (CAP).
2017-08-30 English
Opthea Appendix 4E and Annual Report 2017 89 pages 7.0MB
Regulatory Filings
2017-08-29 English
Appendix 4G and Corporate Governance Statement 2017 20 pages 277.1KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G' and is described as a 'Key to Disclosures Corporate Governance Council Principles and Recommendations' for Opthea Limited for the financial year ended 30 June 2017. It references compliance with ASX Listing Rules 4.7.3 and 4.10.3, which require lodging a corporate governance statement with the ASX at the same time as the annual report. The document contains detailed disclosures about corporate governance practices, board structure, and compliance with governance recommendations. It is not the annual report itself but a governance disclosure document related to the annual report. The document is lengthy (15,000 characters) and contains substantive governance information, not just an announcement or a brief summary. This fits the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. Therefore, the correct classification is CGR with high confidence.
2017-08-29 English
Opthea Presents Further Positive Data from OPT-302 Ph1/2A 3 pages 269.7KB
Regulatory Filings Classification · 90% confidence The document is an ASX and media release dated 15 August 2017 from Opthea Limited announcing additional positive data from a Phase 1/2a clinical trial of OPT-302 for wet AMD. It includes detailed clinical trial results, study design, and background information about the drug and disease. The document is a press release presenting clinical trial data and does not contain financial statements, regulatory certifications, or voting results. It is not a full annual or interim report, nor a call transcript or investor presentation. The content focuses on clinical trial results and company product development updates, typical of a Capital/Financing Update or general company announcement. However, since it is primarily a clinical trial data announcement and not a financing or capital structure update, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2017-08-14 English
Opthea Presents at the Ophthalmology Innovation Summit 3 pages 311.1KB
Investor Presentation Classification · 90% confidence The document is an ASX and media release dated 11 August 2017 from Opthea Limited. It announces that the CEO presented at the Ophthalmology Innovation Summit, describing the content of the presentation about clinical trial data for a drug candidate. The document includes detailed information about the clinical trial, the disease targeted, and the company's background. However, it is not a financial report, earnings release, or regulatory filing. It is a presentation announcement and summary of clinical data shared at a conference, aimed at investors and the public. There is no indication that this is a full investor presentation document, nor is it a transcript or detailed financial report. The document is more of a press release about a presentation event and clinical data update. Given the content and context, the best fitting category is Investor Presentation (IP), as it focuses on financial and strategic information presented to investors, even though it is a summary release rather than the full slide deck. Confidence is high due to the detailed description of the presentation and clinical data relevant to investors.
2017-08-10 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.